Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events). $23 million of 8.00% convertible notes targeted for exchange into cash and common stock.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.02 · Unregistered Sales of Equity Securities
- $23 million of 8.00% convertible notes targeted for exchange into cash and common stock
- Notes exchanged represent approximately 69% of outstanding 2028 Notes
- Cash consideration funded from liquidity on hand, indicating near-term cash deployment
- $10.5 million principal remains outstanding after closing, reducing future debt obligations
- Share issuance planned through an unregistered private placement, creating potential dilution based on 21-day VWAP
Item 8.01 · Other Events
- Xeris announced Exchange Agreements on June 11, 2026, potentially reshaping its capital structure
- Exchange consideration and transaction timing remain subject to forward-looking execution risks
- Investors should review Exhibit 99.1 for exchange terms, affected securities, and expected financial impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.